Announced Mon, 27 Jul · 12:04 IST
Q1 FY27 earnings call transcript, strong revenue and EBITDA growth
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDF
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹835.00
prior close
₹834.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.7-0.3-0.6——————————
Up moveDown movePending
AI summary
Granules India posted Q1 FY27 revenue up 22 percent YoY to INR1,477 crores, EBITDA up 37 percent to INR339 crores at 22.9 percent margin, and PAT up 60 percent to INR180 crores. ROCE improved to 18 percent, net debt to EBITDA at 0.07x. Complex generics now 50 percent of finished dosages. Gagillapur remediation complete, 7 of 8 facilities have clean EIR, 9 ANDA approvals pending. FY27 capex guidance held at INR600 crores.
Likely market impact
Strong quarter with revenue and EBITDA growth, near zero debt. Gagillapur FDA clearance and complex generics mix remain key catalysts.